Can a traditional chinese granule ease a common cancer treatment side effect?

NCT ID NCT07355361

Not yet recruiting Symptom relief Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding Huaier Granule to standard care can reduce proteinuria (excess protein in urine) in breast cancer patients who developed it as a side effect of immunotherapy or anti-angiogenic therapy. About 120 women will be randomly assigned to receive either standard care alone or standard care plus Huaier Granule for up to 24 weeks. The main goal is to see if the combination improves proteinuria treatment response after 8 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Huaier Granule
What this could lead to: If it works, this could offer a new way to manage proteinuria as a side effect of cancer treatment, potentially improving quality of life for breast cancer patients.
What could go wrong: This is a small Phase 2 trial, so results are preliminary. The granule may not reduce proteinuria better than standard care, and its long-term safety is not yet established.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER PATIENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer proteinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER PATIENTS PROTEINURIA

Contacts and locations

Locations

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.